Form 8-K Lyra Therapeutics, Inc. For: Feb 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St set to climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast to split cable business from media in NBCUniversal, Sky spinoff
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Triller to acquire SpaceX exposure as treasury asset via fund structure
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
NASDAQ moves to delist Lyra Therapeutics over public shell concerns
February 6, 2026 4:14 PM ESTLyra Therapeutics Inc. (NASDAQ: LYRA) received a delisting determination from NASDAQ on February 2, 2026, according to a company statement based on a staff letter from the exchange's Listing Qualifications Department.
NASDAQ cited the company as a "public shell" under Listing Rule 5101, referencing Lyra's January 12, 2026 Form 8-K filing that... More
